The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | BATTMAN trial: botensilimab and balstilimab in MSS mCRC
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, describes the study design of the Phase III BATTMAN trial (NCT07152821), which will examine botensilimab plus balstilimab versus best supportive care in hepatic and non-hepatic microsatellite stable metastatic colorectal cancer (MSS mCRC). Patients must have received all available therapies, including 5-fluoruracil, oxaliplatin, irinotecan, monoclonal antibodies and either regorafenib or trifluridine/tipiracil, to understand the efficacy of botensilimab in refractory disease. The drug is also being investigated in rectal cancer, colon cancer, neoadjuvant settings and in combination with chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
